Stranica 1 iz 26 rezultatima
Research Background and Rationale At the end of December 2019, pneumonia of unknown origin was detected in the hospitals of Wuhan city, China, and reported to the WHO country office for the first time [1-3]. After a few days, the Chinese government has confirmed the human-to-human transmission of
This is a Phase 2, , randomized (1:1:1), placebo-controlled, 2-weeks, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of potent inhibitor of neutrophil elastase(Inhaled All trans retinoic acid and inhaled isotretinoin in
This is a small pilot study investigating whether there is any efficacy signal that warrants a larger Phase 2B trial, or any harm that suggests that such a trial should not be done. It is expected to produce statistically significant results in the major endpoints. The investigator will examine all
Since Dec 2019, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has resulted in considerable morbidity and mortality throughout the world. On April 21 2020, Italy and US have registered over 187,000 and 855,000 cases of confirmed COVID-19
The study is a randomized interventional comparative Phase III trial. 1000 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study.
Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down
INCB7839 is an inhibitor of the ADAM (A Disintegrin and Metalloprotease) 10 and 17 proteases. Neuronal activity regulates glioma growth through neuroligin-3 (NLGN3). ADAM 10 is the protease responsible for NLGN3 release into the tumor microenvironment and represents a promising therapeutic
Acute ischemic stroke (AIS) has the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. Progressive cerebral infarction (PIS) is a subtype of AIS, accounting for 10% - 40%. Because of the gradual aggravation of neurological deficit symptoms, it has a
Study Type: Interventional, randomized, parallel Assignment and no masking
Study Arms & Intervention: Drug 1: Aspirin, 100mg/day orally; Drug 2: rivaroxaban, 10mg/day orally; Drug 3: low molecule heparin, 4000IU(0.4ml)/day subcutaneous injection; Reference: mechanical prophylaxis.
Follow-up Period:
Significance: Severe injury is a leading cause of death and disability worldwide, affecting approximately 2.8 million individuals and accounting for over 200,000 deaths annually across the United States. Large cohort studies have demonstrated that approximately 64% of trauma-related deaths are due
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of
Several studies have been performed to understand the cellular mechanisms involved in the development of VTE in cancer patients. The pathogenesis of a thrombotic state is linked to the presence of a tumor and is associated with the development of a hypercoagulant state, namely coagulopathy, which
Post-thrombotic syndrome (PTS) is a problem that can develop in nearly half of all patients who experience a deep vein thrombosis (DVT) of lower limbs. PTS symptoms include chronic leg pain, swelling, redness, and skin ulcers. PTS lowers patients' quality of life after DVT, specifically with regards
Background
Coronary atherosclerosis is responsible for the initiation of acute myocardial infarction with plaque rupture leading to acute coronary thrombosis and myocardial infarction. Current treatment in the acute phase involves re-establishing vessel patency by percutaneous coronary intervention
Fibrinolysis is a process to lyse clot formed by thrombin. It starts with activating plasminogen to plasmin by the endogenous tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). These activator are found in the endothelium, granulocytes and monocytes. Plasminogen activator
Atrial fibrillation (AF) is one of the most common cardiac arrhythmia in medical practice in both the clinical and hospital settings. In addition to a three-fold increase in the risk of mortality, AF patients are at an increased risk of developing a stroke. This risk increased from 6.7% for those